....Small Rise In Drug Prices

18 June 1995

Average drug price increases for all prescription products in the USA were only slightly higher in the first quarter of this year compared to the like, year-earlier period, according to the First Quarter Drug Price Report from First DataBank, which noted that the average price increase in the first quarter was 1.1%, compared with 0.9% in 1994.

Nevertheless, this year's drug prices mark the first upturn in the rate of increase for any first quarter in the last five years. Increases for single source products, the only category analyzed in the report which did not move from last year's low rate of increase, mirrored last year's first quarter at 1.1%. Multiple source products moved up from 0.9% to 1.1%. Branded products available from multiple sources had an increase of 1.5% during 1995's first quarter compared with 1% in 1994 and 1.9% in 1993. All three periods showed slower increases than the 3% seen in 1992 and 3.3% in 1991. Generic products had a slight upturn, from 0.8% to 1%.

Products from the top 25 companies followed the general slight upward trend of drug price increases in this quarter, but were still lower than the same period in previous years. Prices in this category increased 1.2% in the first quarter of 1995 compared with 0.7% in the like, 1994 period. Both represent slower increases than the 2.4% registered in 1992.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight